Glucowatch to be given expedited review:
This article was originally published in Clinica
Executive Summary
The US FDA will review Cygnus' premarket approval (PMA) application for the GlucoWatch automatic, non-invasive glucose monitor under expedited review status. This is given to technology which is seen as in the public's health interest and therefore a priority for approval. Redwood City, California-based Cygnus submitted the final module of its PMA last month (see Clinica No 861, p 17).